• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:WO1981001367A1
    申请号:PCT/EP1980/000136
    申请日:1980-11-21
    公开日:1981-05-28
    发明作者:W Pierpaoli；G Maestroni
    申请人:Cell Eng Ag；Choay Sa；W Pierpaoli；G Maestroni；
    IPC主号:A61K35-00
    专利说明:
    [0001] A WATER SOLUBLE FRACTION CAPABLE OF CONTROLLING THE IMMUNE
    [0002] REACTIONS OF A HOST AGAINST ALLÜGENEIC CELLS OR TISSUE, THE
    [0003] PHARMACEUTICAL COMPOSITIONS CONTAINING SAID FRACTION AND A
    [0004] PROCESS FOR PREPARING THE LATTER
    [0005] The invention relates to a water soluble fraction from the bone marrow having biological activities among others that of Controlling the immune reactions of a host ag a i n s t allogeneic cells or tissue, particularly host versusgraft reaction (HVGR) and so-called graft versus-host reaction [GVHR] in transplantation of allogeneic incompatible bone marrow, of promoting engraftment of allogeneic marrow in vivo and of protecting the host against irradiation and the consequences of irradiation. It has already been published that viable bone marrow cells were capable of Controlling immu no log ica l reactions (HVGR and GVHR) ensuing when immunogenet ica l different bone marrow is transplanted into a lethally irradiated host (iramunity). Mors particularly, it has already been found that bone marrow cells were liable of facilitating engraftment of foreign cells or tissue (allogeneic or xenogeneic in a host) when administ ering them to said host according to a determined protocol or regimen including a total body irradiation procedure, the latter aiming at destroying the host's own immune system and at facilitating the Substitution for it of an immune System of foreign origin.
    [0006] More particularly, it has been found that the treatment of mice, which comprises administering to them rat bone marrow cells, then subjecting them shortly thereafter to lethal total body irradiation (TBI) and subsequently readministering new bone marrow cells, resulted in remarkable protection of said mice against radiation injury and when the bone marrow cells administered after TBI were. of xenogeneic origin (i. e. rat)- facilitation of marrow engraftment and induction of a persisting xenogeneic (rat) chimerism in said mice ("A new pre-irradiation conditioning regimen which protects against radiation injury and facili tates engraftment of xenogeneic bone marrow"- Walter Pierpaoli & Georges J. M. Maestroni, Scand. J. Haematol. (19791, 22, 165-172. The operational procedure preceding TBI was -and will hereafter be in relation to the invention- designated by "preconditioning" while the designation "post-conditio ning" referred -and will also hereafter refer- to the administration of material of bone marrcw origi n after TBI. On utilizing the model of xenogeneic [rat to mou se) marrow transp lantation it was established that the critical factors for success included a sufficient number of viable bone marrow cells before and after TBI, the timing and the route of inoculation , each of these had to be correctly poised to assure protection against secondary disease, long term survival and the development of chimerism.
    [0007] The present invention sterns from the discovery that the viable marrow cells were exerting this strikingly favorable effect via synthesis and/or secretion, in the host, of components facilitating engraftment of the transplanted incompatible marrow after lethal TBI.
    [0008] Particularly, it has been found that the abovesaid favorable effect can be attributed to a water-soluble biologically active fraction obtainable from the physiological inter-cellular medium of bone marrow of any mammalian animal, particularly, after Separation therefrom of the bone marrow cells themseIves.
    [0009] This discovery was all the more unexpected as the physio logical inter-cellular medium (bone marrow supernatant SN) as such did not exhibit substantial, unless Special care is taken to avoid inactivation of the biologically active fraction, and reproducible activity in a testing system as hereabove defined and as said biologically active fraction tends to be inactivated when the pH is neutral or tends to fall below 7.0 and contains both inhibitors and activators of bone marrow functions.
    [0010] The water-soluble biologically active fraction according to the invention which is obtainable from the physiologically inter-cellular medium of bone marrow has the following characteristics :
    [0011] - it is substantially free of inhibitors which have molecular weights essentially lower than about 30 000 ;
    [0012] - it is lyophi lizable without loss of biological properties ;
    [0013] - it exhibits the hereafter defined biological activities in the form of a solution having a pH of at least 7, preferably from 7.2 to 7.6 ;
    [0014] - it stimulates 3H-thymidine incorporation by bone marrow cells in vitro and in vivo ;
    [0015] - it allows the engraftment of allogenic bone marrow and induces persistent chimerism in previously lethallyirradiated animals, as well as survival of the latter ;
    [0016] - the activity is not species-specific ;
    [0017] - its activity is destroyed by heating at 70°C for 30 mn ;
    [0018] - its UV spectra shows a peak of absorption at 280 nm.
    [0019] Further preferred fraction according to the invention is also substantially free of the components contained in the phys io logica l inter-cellular medium of bone marrow which both have molecular weights less than 100 000 and consist of inhibitors of the biological activity as hereabove defined of the fraction according to the invention. Particularly a preferred fraction is substantially free of those inhibitors that are filtrable through a filtration system, such as a microporous mernbrane, allowing the separation and removal of components having molecular weights essentially lower than 100 000, from said physiologica l int er-cellular medium, or a buffered or a saline solution thereof.
    [0020] It flows from the preceding definitiσns that, apperently, the whole physiological inter-cellular medium of bone rrarrow contains inhibitors of the activity of the biological fraction according to the invention. which inhibitors seem to have molecular weights not exceeding about 30 000.
    [0021] The invention also contains a process for obtaining said biological fraction from bone marrow, which comprises separating and recovering the phy siological inter-cel lular medium from the bone marrow cells, then further separating from said inter-cellular medium, if need be in the form of a diluted solution in a physio logical, buffered or saline solution, those components which are filtrable through a filtration system, more particularly a microporous membrane, allowing the Separation of components having molecu lar weights not above about 30 000, preferably not above 100 000, and recovering the biologically active fraction freed from the abovesaid components of lower molecular weights.
    [0022] Preferably, the pH of the medium is at all times maintained at a value not lower than 7.0, preferably from 7.2 to 7.6.
    [0023] For carrying out the Separation of the physiological inter-cellular medium from the bone marrow cells, the bone marrow is preferably suspended beforehand in a physiological solution, particularly saline solution or a buffered solution whose pH has been adjusted between 7.2 and 7.6 and, if need be, the cells are separated after gentle dissociation of the bone marrow tissue so controlled as to avoid possible destruction of the cellular material. An advantageous buffered solution consists of
    [0024] Hanks' medium or Earle's medium pH 7.4.
    [0025] The temperature under which all the above operations may be carried out is preferably below ambient, preferably between 0 and 5°C.
    [0026] This procedure thus enables a biologically active fraction to be obtained, which is liable of controlling the immune reactions under conditions substantially the same as those which have been mentioned above in connection with whole bone marrow cells, and as this will be illustrated hereafter.
    [0027] The activity of the biological fraction of the invention is not species - specific. It is fully devoid of toxicity.
    [0028] The fraction of the invention is also characterized by the ability that it has to react immunologically with antibodies formed in an hetεrologous host against thε fractionas obtained by the process herein defined (hereafter designated as MRF) .
    [0029] In order to investigate the organ and tissuε specificity of marrow regulating factors (MRF), the following technique can be adopted and is hereby deεcribed in its essential lines.
    [0030] Sheep or goats are repeatedly injected. with human or rabbit MRF intramuscu lar ly (four times at four-week intervals) . One week after the last injection, blood is collected and serum separated, divided into aliquots and frozen. Theanimals are then injected once more and serum is collected one week afterwards. The quantity of MRF injected each time is of 10 mg/sheep. MRF is dissolved into saline from the lyophilized state, prior to injection.
    [0031] Aliquots of the sheep anti-rabbit MRF and sheep anti-human MRF are repeatedly absorbed with washed and packed rabbit thymus and spieen cells, in order to remove the antibodies which are not specifically directed against MRF but against other, different and organ -specific antigens. Antibodies against MRF are determined by the direct precipitin assay or by the passive haemagglutination technique with formalin-treated and antigen (MRF) -coated sheep red cells.
    [0032] The combination of these serological techniques and of radio immunoassay (RIA) with radioiodinated ( 125I) MRF allows to establish :
    [0033] 1° the presence of anti-MRF antibodies and their titer ;
    [0034] 2° the presence of organ- specific (particularly bone marrow) antibodies ; 3° the possible cross-reactivity of human and rabbit MRF (agglutination-inhibition test) ;
    [0035] 4° the presence of MRF in tissue extracts or preparations of unknown origin (immunological identification) ; 5° the possible organ-specificity but not biological species-specific activity of human and rabbit MRF (e. g. rabbit MRF is active on human BM cells and human MRF is active on rabbit BM cells). To sum up, serological tests and RIA will allow the Identification on MRF as a possible unique combination of substances with organ-specificity, non-species specifi city of biological activity.
    [0036] The invention also concerns pharmaceutical compo sitions containing such fraction in association with pharmacological vehicle enabling the adminis tration to a host, i. e. by the parenteral, such as the intravenous, route. The invention will be further illustrated in a non-limitative manner by the following description of a preferred mode of extraction of a biological active fraction according to the invention from the bone marrow of animals, such as mice, rats, rabbits, sheep, and of their biological properties.
    [0037] The solution in saline of the abovesaid physiological inter-cellular medium will be hereafter referred to as "bone marrow supernatant", and the biologically active fraction of the invention as "marrow regulating factor" (MRF). I - DESCRIPTION OF THE METHOD USEO FOR PREPARATION OF BONE MARROW SUPERNATANTS (SN) FROM WHICH THE MARROW REGULATING FACTOR (MRF) IS EXTRACTED
    [0038] Young adult donors (groups of ten, male or female rabbits between 1.5 and 2.0 kg body weight) were killed by cervical dislocation. The long bones were isolated and put into refrigerated TC 199 or saline (NaCl 0.9 %). The bones were then cut at the extremities and TC 199 or saline was flushed repeatedly through the bones to expel all the marrow, including fat tissue and connective tissue and all that make up the inter-cellular medium of the bone marrow. The material (clots of marrow, fat, other tissues) was then dissociated by using a large syringe without needle, delicately aspiring and expelling the suspended material which was always kept in melting ice, until no cell aggregates were visible. The number of cells in the Suspension ranged between
    [0039] 50 and 100 x 106/ml of SN. At this stage, the whole initial Suspension of material was centrifuged in a refrigerated centrifuge at 5°C for 30 minutes at 10,000 x g and the fat condensed at the top of the tubes was eliminated by aspiration. The rest of the supernatant was collected in plastic Containers and frozen immediately at -30°C. The cells were discarded. All this preparatory work was carried out under sterile conditions. SN is intended to be the original Suspension medium in which the bone marrow cells were dissociated and suspended. The pH of all cell suspensions, and preparations of SN was kept or corrected at 7.2 to 7.5. Prεparation of MRF from rabbit bone marrow supernatant (SN)
    [0040] After thawing the SN, it was centrifuged for 20 minutes at 40 000 x g in a refrigerated centrifuge to remove all possible particles and precipitate. The SN was then passed over a Diaflo XM 100 filtration membrane (MW : cut off 100 000) ; Amicon Co., Oosterhout, Holland, using an Amicon Model 202 Cell, to eliminate the fraction containing separated compounds having apparent molecular weights less than 100 000. In some experiments the latter fraction was then passed over a Diaflo XM 30 filtration membrane (MW : cut off 30 000) in order to further remove components which have molecular weights less than 30 000. An equal volume of water was used in each experiment to wash the material which did not pass through the filter. The materials remaining on the filters were withdrawn with a syringe and lyophilized.
    [0041] The different fractions tested hereafter were designated as follows : "MW > 100 000" is the MRF fraction freed from components having molecular weights less than about 100 000 ;
    [0042] "MW > 30 000" is the fraction freed from components having molecular weights less than about 30 000 ;
    [0043] "MW < 100 000" is the fraction freed from components having molecular weights above 100 000 ;
    [0044] "MW < 30 000" is the fraction freed from components having molecular weights above 30 000. These different fractions are referred to in the tables hereafter under the above designations.
    [0045] The biological activity of the MRF fractions as mea sured by activation or inhibition of 3H-thymidine incorpora tion by bone marrow cells in vitro is made inactive by lowe ring the pH below 7.0 and by heating at 70°C for 30 minutes.
    [0046] In an another experiment 150 mg of the material "MW > 100 000" were dissolved in 5 ml of N-ethylmorpholine acetate buffer 0.1 M pH 7.4, After centrif ugat ion (10 minutes, 40,000 g) an insoluble pellet was obtained and washed with 2 ml of same buffer. The supernatant + washings (7 ml) were mixed and introduced on a column (2.5 cm x 90 cm) of a polyacry lamidagarose gel beads commercialized under the designation ULTR0GEL AcA34 that had been equilibrated with the same 0.1 M pH 7.4 Nethylmorpholine acetate buffer.
    [0047] The gel filtration took place under the following conditions :
    [0048] - flow rate : 13,5 ml/hr - fractions volume : 3 ml
    [0049] - temperature : + 4°C.
    [0050] The pattern obtained is shown in fig. 1, which is representative of the contents of the successively eluted volumes (in ml) as measured in UV spectrophot ometry (absorbance at 276 nm).
    [0051] Four fractions were obtained as indicated, respectively fractions :
    [0052] . A (27 mg),
    [0053] . B (74 mg), . C (18 mg),
    [0054] . D (3.6 mg).
    [0055] Total yield (by weight) : 82 %.
    [0056] The horizontal bars numbered 1, 2, 3, 4 and 5 shown on the figure, correspond to MW markers, respectively :
    [0057] 1 blue dextran (MW of about 2,000,000), 2 bovine serum albumin (MW of about 67,000), 3 ovalbumin (MW : 47,000) 4 : carbonic anhydrase (MW : 30.000)
    [0058] 5 : chymotrypsinogen (MW : 25,000)
    [0059] Fraction B of fig .1 was also found to be highly active in the tests hereafter illustrated and which bring forth the activity of "fraction of MW > 100,000".
    [0060] Fraction B comprises componeπts which can roughly be stated to be formed of components having molecular weights ranging from about
    [0061] 40,000 to about 70,000.
    [0062] II - BIOLOGICAL ACTIVITIES
    [0063] 1° Materials and methods
    [0064] Animals : the animals used were mice, which have been bred under specific pathogen-free conditions and then maintained, as adults, under strictly standardized and control led hygienic conditions. However, no Special precautions were taken to avoid pathogenic bacteria or viruses. No antibiotics were administered via drinking water either before or after irradiation.
    [0065] Donors or recipients of bone marrow were inbred young adult (8-12 weeks old) C578L/6, DBA/2 and C578LxA/J F1 hybrid mice. The rabbits used were an outbred Swiss strain, 1.5 to 2 kg body weight. They were used as donors of xenogeneic marrow for preparation of supernatant (SN) from which the fraction containing marrow regulating factors were separated. This fraction is hereafter referred to as MRF. Preparation of bone marrow cell suspensions
    [0066] Suspensions of bone marrow cells were freshly prepared 2-3 hours before inoculation. Mice were killed by cervical di s location, the long bones (humeri, tibiae and femurs) were isolated and cut at the extremities. Ice-cold TC 199 medium was flushed repeatedly through the cavities by a syringe with a needle fitting the bone size. The pooled marrow was gently dispersed by a needleless syringe and filtered trrough gauze. The cells were then washed 2-3 fold by low speed centrifugation, using ice-cold TC 199 medium. The fi nal cell suspensions were adjusted to the desired number and volume. Quantities varying from 20 to 40 x 106 cells per donor mouse could be harvested. The cells were administered in a volume of 0.5 ml per mouse, i. v. Trypan-blue exclusion tests showed that over 95 % of the cells were viable just before their inoculation. Irradiation
    [0067] A dose of 850 to 900 rads total body irradiation (TBI) was given to the recipients depending on the known strain sensitivity to irradiation (5). This does led to death of all untreated mice within 8-15 days. The irradiation apparatus was a Cobalt Gammatron 3 (6 000 Curie). Field size was 30 x 30 cm, main focus distance was 90 cm. No filters were used.
    [0068] Transplantation of allogeneic marrow a ) Pre-conditioning regimen
    [0069] When this regimen was adopted the mice were injected i. v. 1.5 to 2.0 hours before Irradiation with 1.0, 2.5 or 5 mg of rabbit MRF. The lyophilized material (fraction with MW > 100,000) was dissolved in TC 199. The volume injected was 0.5 ml. Controls were injected with cells or medium with out cells or medium without MRF. b ) Post-conditioning regimen The mice were injected 24 hours after TBI with 35 to 37 x 106 washed bone marrow cells. Depending on the experimental plan the cells were injected alone or suspended in the medium containing the fractions of the MRF. The cells were resuspended in the medium (TC 199, pH 7.4) containing MRF shortly before i. v. inoculation. In some tests the cells and the MRF were injected separately (Table 1). Tests for chimerism . a ) Hemoglobin migration pattern
    [0070] At monthly intervals after TBI, all mice were individually tested for chimerism of the erythroid cell line.
    [0071] A few drops of blood were taken from the retroorbital plexus, suspended in heparinized saline and washed repeatedly. The washed blood cells were hemolyzed in 1 : 5 cell water volume. The pattern of hemoglobin migration was examined by celluloseacetate electrophoresis. The strips were stained with Amido Black. Engraftment of the donor erythropoietic line corresponded to complete chimerism as confirmed by skin grafting. b ) Skin grafts
    [0072] In the Situation of cross- transp lantat ion of bone marrow from or into C57BL/6 or OBA/2 donor/recipient, donor skin was grafted an groups of allogeneic marrow recipients.Grafting was by conventional technique ; the corsets were removed after 8-10 days and the viability of the grafts was checked daily. The graft was considered as rejected when the first signs of infiltration, oedema and induration appeared.
    [0073] They were consi dered as accepted only when none of thesesigns were discarnible and luxuriant hair grew on the transplanted skin. Incorporation of 3H-thymidine by bone marrow cells in vitro 6- 3H-thymidine, 27 Ci/mM was purchased from the
    [0074] Radio-Chemica l Center, Amersham, England. Washed bone marrowcells freshly taken from adult C57BL/6 mice were incubated for 1, 2 and 3 hours in sealed tubes in the presence of 2 μCi of 3H-thymidine. Samples were in triplicate. Each tube contained 2 x 10 washed bone marrow cells suspended in 1 ml of medium TC 199, or in TC 199 with 200 ug of the Ultrafiltration fractions of the original supernatant of rabbit bone marrow cell suspensions (see above preparation of MRF). The pH of the medium was adjusted to 7.5. After 1, 2 and 3 hours of incubation, 0.1 ml of 10 % sodium dodecyl sulpha'te (SDS) was added to each tube. After a vigorous shacking, DNA was precipitated at 4°C for 15 minutes by adding to each tube 1 ml of 10 % trichloroacetic acid (TCA). The precipitate was collected on Whatmann GF/C glass fiber filters and washed with 5 % TCA and absolute ethanol. The filters were dried and the activity was measured in a LKB-Wallac 81 000 liquid scintillation counter.
    [0075] The results of the different tests run according to the invention are presented in the tables hereafter.
    [0076] The comment under each table provides the Information appropriate for the understanding of the experimentalconditions, to the extent where it does not appear in the present description.
    [0077] The "ratio MRF/BM cells", where appropriate, is the ratio of the number of cells which in the bone marrow of origin accompanied the amount of MRF used in the experiments concerned to the number of cells contacted with said amount of MRF in the solvent also identified in the corresponding column.
    [0078] The experimental conditions appear in the headings of the different tables.
    [0079] In tables 1-5, there is indicated in the right hand column the operational conditions, particularly the nature of the components contacted with one another.
    [0080] In table 7, the numbers, if any, in the sub-columns under the headings "h-" and "h+" indicate the times in hours of injection of the MRF before and after TBI respectively.
    [0081] In the sub-column with the sub-heading "No of BM cells (x 106)" under the general heading "Post-conditioning" reference is made to the number of bone marrow cells injected together with the corresp onding amount of MRF, if any, in the left hand-side neighbouring sub-column.
    [0082] TABLE 1 it shows that the activity of the MRF in enhancing
    [0083] 3H-thymidine incorporation is depending on the pH of the incubating medium (compare lines 1, 2 and 3 which are the controls with lines 4, 5 and 6).
    [0084] It shows also that the activity is not speciesspecific (compare lines 2 and 5 with 7 and 8). Lines 5 and 7 show that rat SN is active on rat bone marrow cells as well as on mouse cells. TABLE 2 - TABLE 3
    [0085] Experiment reported in Table 2 is conducted usingwhole supernatant (SN), while experiment reported in Table 3 is conducted using ultrafiltrated SN (MRF) on Amicon Diaflo Membrane 100,000 and 30,000. The result of each case is compared to the one obtained with TC 199 medium.
    [0086] Table 2 shows that the whole supernatant (SN) induces less 3H-thymidine incorporation than the reference medium
    [0087] TC 139 ( lines 1 and 3). "Fraction above 30,000" stimulates the 3H-thymidine incorporation while "Fraction below 30,000" inhibits the incorporation (lines 1 and 3 and line 2). Further the "Fraction below 100,000" shows no effect on incorporation (line 4) .
    [0088] Thus one can see that the SN contains also inhibitörs which prevent the Stimulation of 3H-thymidine incorporation by the activating factor.
    [0089] This experiment shows that inhibitory fractions and stimulating fractions can be separated by the ultrafiltration of SN on Amicon Diaflo Membrane 100,000. Further experiment 2 of Table 2 shows that the action is not due to a non-specific mitogenic effect of heterologous protein (rabbit in that case) as BSA does not affect the incorporation (line 2) over that of TC 199 (line 3). TABLE 4 The experiment allows for the comparison of the respective actions of the MRF fraction ("MW above 100,000") before and after treating at 70°C for 30 minutes.
    [0090] The results presented on Table 4 show that after 1, 2, as well as 3 hours, the incorporation is much lower forthe heated product. Thus, heating seems to destroy the stimulating factor. TABLE 5
    [0091] Ultraf iltrated MRF fractions "above 100,000" are here compared with fractions "below 30,000" and "below 100,000" for their Stimulation of 3H-thymidine incorporation in vitro.
    [0092] Here again one sees that only the fraction above 100,000 MW is able to stimulate the incorporation of thymidine by bone marrow cells. TABLES 6 AND 7
    [0093] In these two experiments the MRF and the thymidine are inoculated intravenously into groups of mice. The animals receive I. V. 500 μg or 1 mg of the fraction and 2 or 4 μCi of thymidine in 0.1 or 0.5 ml of saline. Mice are sacrificed 1 and 2 hours after the injection.
    [0094] Comparisons are made with control groups of mice trsated with BSA and thymidine or with "heated" MRF fraction and thymidine.
    [0095] Bone marrow of one tibia is collected and adjusted at 2,10 cells per ml and processed as described in the in vitro experiment. Conclusion : the "fraction above 100,000" causes, also in vivo, increase of the incorporation of 3H-thymidine by mouse bone marrow cells.
    [0096] This experiment confirms that the activity is not due to an heterologous protein ( table 7) and that it is destroyed by heat (table 6).
    [0097] 2° Pharmacological activity - Bone marrow transplantation
    [0098] The bone marrow transplantation is a therapy which can be considered for hematopoietic malignant disorder, for instance leukemia, aplastic anemia, etc. Until now such transplantation has never been achieved when genetical incompatibility between donor and recipient is present.
    [0099] The following experiments show that MRF allows engraftment of bone marrow bgtween incompatible donor and recipient by inf luencing positively the engraftment of the foreign marrow.
    [0100] Two different modeis have been used : one where animals are totally genetically incompatible, DBA 6 donors and C57BL/6 recipient, see table 8, and one with semi-compatible donors and recipients : C57BL/6 donors and hybrid C57BL/6XA/J F1 recipients (see table 9).
    [0101] The purpose of the experiment was to achieve persisting BM allogeneic chimerism. The criteria for the success (persistent chimerism) are : - migration pattern of hεmoglobin showed by cellulose acetate electrophoresis. Donor and recipient have genetically different patterns of hemoglobin. Chimeric mice carry the hemoglobin of the bone marrow donor ;
    [0102] - skin grafting : permanent chimera accept permanent by skin graft from the marrow donor ;
    [0103] - another criteria for successful engraftment of allogeneic marrow is health condition and survival without appearance of secondary diseose under conventional conditions
    [0104] (so-called GVHD or Runting disease).
    [0105] Animals were treated as described below with ultrafiltrated MRF fraction dissolved in TC 199-0.5 ml. TABLE 8
    [0106] This table reports the results of attempts to produce survival of a first "strain of mice successively pre-conditioned", then irradiated and finally post-conditioned and injected with bone marrow of another strain of mice known to be normally genetically totally incompatible at the H2 locus with the first one. The experiment was carried out as follows.
    [0107] Recipients are injected intravenously 1 to 2 hours before irradiation with the MRF fraction, then they are lethally irradiated and 24 hours after irradiation they receive I. V. washed bone marrow cells of the donor suspended in a medium containing the MRF fraction.
    [0108] The pre- and post-conditioning with the MRF fraction "above 100,000" under the above condition allowed for good survival and persistent chimerism as demonstrated by hemoglogin patterns and permanent take of skin graft (from DBA/2 donors in the surviving animals).
    [0109] The animals surviving after 6 months are in perfect conditions and show no sign of secondary disease. It is worht while noting that füll chimerism is obtained in mice which were both pre-conditioned and post-conditioned with MRF. Preferably said post-conditioning takes place, at least 24 hours after total body irradiation. In such instance pre-conditioning can even be dispensed with. More generally transplantation of any tissue or cells to be grafted into a host should take placc not earlier than at least 24 hours after body irradiation.
    [0110] It has been found further that MRF counteracts the accelerating effect induced by T- lymphocytes, particularly of spieen cells, on graft rejection.
    [0111] Bone marrow transplanted from a same animal into one having a genetic deficiency of the immune system is liable of overcoming the disease liable of being induced in the latter animal. TABLE 9
    [0112] This table reports the results obtained under simi lar conditions, yet with semi-compatible donor/recipient strain combination. No pre-conditioning is needed for induc tion of chimerism. In this experiment füll success has been obtained with injection of MRF and BM cells after Irradiation only, and permanent chimerism is demontrated by hemoglobin pattern for all of the surviving animals. 3° Toxicity study
    [0113] 5 mg dose of MRF has been injected into each of 100 mice. No toxic effect has been observed.
    [0114] Repeated daily injections of 2 mg over a period of 1 month have not produced any evidence of toxicity. Animals were in perfect condition. They developped normally with no symptom of disease. The product was very well tolerated. The possible induction of chimerism by the biological fraction according to the invention, with an even greater rate of success as that which results from the tables, when the experiments are carried out with animals recipiept under more sterile conditions, coupled with the great tolerance which it shows in vivo, thus are liable of providing a new therapeutic and experimental basis for the control of HVG reaction or GVH reaction in bone marrow transplantation. Its practical application in organ- and bone marrow transplantation, in auto-immune disease and in the immunotherapy of cancer, for instance leukemia and breast cancer, are but a few of the most compelling areas of its application. The invention is thus concerned with the pharmaceutical compositions containing said fraction in dosage unit form associated with classical pharmaceutical vehicles suitable for any appropriate form of administration. Particularly it relates to injectable, sterile solutions, at a pH not lower than 7, preferably from about 7.2 to about 7.6, containing effective doses of said fraction. Particularly it relates also to lyophilized fractions, or lyophilized preparations containing said fractions in association with a vehicle so selected as to enable the extemporaneous formation of such solutions at a pH ranging from about 7.2 to about 7.6, by the addition thereto of an injectable volume of either sterile water or any appropriate physiological liquid vehicle.
    [0115] The invention does also concern the biological standard reactants which can be formed with the MRF fraction, particularly as a means enabling comparative assessments of the activities of other tested preparations with respectto the control of acquired immunity, bone marrow reconstitution or protection with respect to radiation.
    [0116] The invention finally consists of a method for grafting heterologous tissue or cells into a host which comprises destroying the host's immune defenses, such asby irradiation, treating said host with an efficient dose of MRF as well as casing said graft thereafter, preferably ot 24 hours after the destruction of the host's immune defenses.
    [0117]
    [0118]
    [0119]
    [0120]
    [0121]
    [0122]
    [0123]
    [0124]
    [0125]
    权利要求:
    Claims
    1. Water soluble biologically active fraction obtainable from the physiologically inter-cellular medium of bone-marrow, characterized in that : - it is substantially free of those components of said physiological inter-cellular medium which are filtrable through a filtration system such as a microporous membrane allowing the separation and removal from said medium of components which have molecular weights essentially lower than about 30 000 ;
    - it is lyophilizable without loss of biological properties ;
    - it exhibits the hereafter defined biological activities in the form of a solution having a pH of at least 7, preferably from 7.2 to 7.6 ;
    - it stimulates 3H-thymidin incorporation by bone marrow cells in vitro and in vivo ;
    - it allows the engraftment of allogenic bone marrow and induces persistent chimerism in previously lethally irradiated animals, as well as survival of the latter ;
    - the activity is not species-specific ;
    - its activity is destroyed by heating at 70°C for 30 mn ;
    - its UV spectra shows a peak of absorption at 280 nm .
    2. Fraction according to Claim 1, characterized in that it is free of the components contained in the physiological inter-cellular medium of bone-marrow which are filtrable through a filtration system such äs a microporous membrane, allowing the separation and removal of components having molecular weights essentially lower than 100 000.
    3. Process for obtaining the bio logical fraction from hone-marrow according to Claims 1 and 2, characterized in that it conprises separating and recovering the physiological intnr-cellular medium from tho bone-marrow cells. then further separating from said inter-cellular medium, if need be in the form of a diluted solution in a physiological, buffered or saline solution, those components which are filtrable through a filtration system, more particular ly a microporous membrane, allowing the Separation of com¬ponents having molecular weights not above about 30 000, prtferably not above 100 000, and recovering the biological ly active fraction freed from the above said components of lower molecular weights.
    4. Process according to claim 3, characterized in that the pH of the medium is at all time maintained at a value not lower than 7.0, preferably from 7.2 to 7.6.
    5. Process according to Claims 3 and 4, characterized in that the bone-marrow is preferably suspended beforehand in a physiological solution, particularly saline solution or a buffered solution whose pH has been adjusted between 7.2 and 7.6 and, if need be, the cells are separated after gentle dissociation of the bone-marrow tissue so controlled as to avoid possible destruction of the cellular material.
    6. Process according to claim 5, characterized in that the buffered solution consists of Hanks' medium or Earle's medium pH 7.4.
    7. Process according to anyone of Claims 3 to 6 characterized in that the operations are carried out below ambient temperature, preferably between 0° to 5°C.
    8. Pharmaceutical composition containing the fraction according to anyone of Claims 1 or 2, in association with pharmaceutical vehicle enabling the administration to a host, by the parenteral, such as the intravenous, route .
    类似技术:
    公开号 | 公开日 | 专利标题
    Williams et al.1983|Granulomatous inflammation--a review.
    DiSaia et al.1972|Cell-mediated immunity to human malignant cells: A brief review and further studies with two gynecologic tumors
    Greene et al.1978|Mechanisms of regulation of cell-mediated immune responses: I. Effect of the route of immunization with TNP-coupled syngeneic cells on the induction and suppression of contact sensitivity to picryl chloride
    EP0097518B1|1989-10-11|Monoklonaler Antikörper
    AU606666B2|1991-02-14|Active specific immune suppression
    Lau et al.1983|Pancreatic islet allograft prolongation by donor-specific blood transfusions treated with ultraviolet irradiation
    Gorer1961|The antigenic structure of tumors
    US6110458A|2000-08-29|Cancer therapy utilizing ex vivo gene transduction
    Old1988|Tumor necrosis factor
    DE69533189T2|2005-07-21|Immuntherapie von krebs mit allogenen lymphocyten
    Burnet1959|Auto-immune disease: I. Modern immunological concepts
    Mills et al.1983|Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells.
    Tutschka et al.1979|Use of cyclosporin A in allogeneic bone marrow transplantation in the rat
    Filipovich et al.1984|Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease
    KR101823627B1|2018-01-30|특이적 면역 관용을 유도하기 위한 조성물
    US4372945A|1983-02-08|Antigen compounds
    Gaspari et al.1988|Induction and functional characterization of class II MHC | antigens on murine keratinocytes.
    US6607722B2|2003-08-19|Methods for inducing the differentiation of monocytes into functional dendritic cells
    KR100514957B1|2005-11-25|수지상세포자극인자
    Fishman1961|Antibody formation in vitro
    Hellström et al.1970|Colony inhibition of fibroblasts from chimeric dogs mediated by the dogs' own lymphocytes and specifically abrogated by their serum
    CA2413237C|2013-09-10|Alteration of cell membrane for new functions
    Blaese et al.1993|Treatment of Severe Combined Immunodeficiency Disease | due to Adenosine Deaminase Deficiency with CD34+ Selected Autologous Peripheral Blood Cells Transduced with a Human ADA Gene |. National Institutes of Health
    US8512712B2|2013-08-20|Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions
    US20010038841A1|2001-11-08|Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
    同族专利:
    公开号 | 公开日
    FR2469926A1|1981-05-29|
    CH650154A5|1985-07-15|
    AU6486980A|1981-06-03|
    FR2469926B1|1983-12-30|
    SE8104458L|1981-07-20|
    JPS56501525A|1981-10-22|
    GB2074864B|1984-08-22|
    DK312081A|1981-07-13|
    US4540574A|1985-09-10|
    AU544136B2|1985-05-16|
    GB2074864A|1981-11-11|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    FR1954M|||Rolland Lab A|Extrait de moelle osseuse.|
    FR4070M|1963-05-23|1900-01-01|||
    GB1086689A|1964-12-01|1967-10-11|Alkliam Chemicals Ltd|Pharmaceutically active extracts of bone marrow|
    GB1321570A|1970-11-04|1973-06-27|Alexandre|Composition for the treatment of hair|
    GB1528087A|1975-11-21|1978-10-11|Thomas A|Method of extracting a hyperglycemic factor|
    EP0005404A2|1978-05-03|1979-11-14|Yves Marie Frank Souron|Die Wundheilung förderndes Produkt, extrahiert aus Tierknochenmark|FR2569110A1|1984-08-17|1986-02-21|Ionescu Pantelimon Dumitru|Sang animal et moelle osseuse animale decancerisants, transfusibles aux hommes, procede et appareil pour leur preparation|
    US5482924A|1991-05-06|1996-01-09|Centre National De La Recherche|Proteinaceous compositions having an activity on erythropoiesis|FR1345565A|1962-01-19|1963-12-13|Rolland Lab A|Procédé pour l'obtention d'extraits totaux plus généralement orginaires de tissus viants|
    US3526697A|1966-10-06|1970-09-01|Nevada Pharm Inc|Therapeutic method|JPH0753667B2|1985-08-09|1995-06-07|新技術開発事業団|骨髄移植療法補助剤|
    AU4767693A|1992-07-21|1994-02-14|Nikolaenko, Alexandr Nikolacvich|Biologically active agent having immunomodulating properties,method for its obtaining and pharmaceutical preparation bases on it|
    MD838G2|1992-07-21|1998-09-30|Alexandr Nicolaenco|Remediu biologic activ cu proprietate imunomodulatoare, procedeu de obţinere a lui, preparat pe baza lui şi procedeu de normalizare a stării fiziologice a omului şi animalelor|
    法律状态:
    1981-05-28| AK| Designated states|Designated state(s): AU CH DE DK GB JP NL SE US |
    1982-03-25| RET| De translation (de og part 6b)|Ref document number: 3050057 Country of ref document: DE Date of ref document: 19820325 |
    1982-03-25| WWE| Wipo information: entry into national phase|Ref document number: 3050057 Country of ref document: DE |
    优先权:
    申请号 | 申请日 | 专利标题
    GB7940392||1979-11-22||
    GB7940392||1979-11-22||DE803050057T| DE3050057A1|1979-11-22|1980-11-21|A water soluble fraction capable of controlling the immune reactions of a host against allogeneic cells or tissue,the pharmaceutical compositions containing said fraction and a process for preparing the latter|
    NL8020431A| NL8020431A|1979-11-22|1980-11-21|Immunosuppressant factor from bone marrow - isolated from inter-cellular medium by removing low-molecular-wt. components|
    DK312081A| DK312081A|1979-11-22|1981-07-13|Vandoploeselig fraktion der er i stand til at kontrollere en vaerts immunreaktion over for allogene celler eller vaev og fremgangsmaade til fremstilling af denne fraktion samt de farmaceutiske praeparater der indeholder fraktionen|
    [返回顶部]